ANI Pharmaceuticals Inc (ANIP)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 2.04 | 1.81 | 2.02 | 1.96 | 1.77 | 1.54 | 1.43 | 1.37 | 1.32 | 1.42 | 1.38 | 1.38 | 1.23 | 1.48 | 1.29 | 1.42 | 1.43 | 1.36 | 1.43 | 1.33 |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 1.84 | 1.68 | 1.30 | 1.28 | 1.30 | 1.24 | 1.19 | 1.50 | 1.29 | 1.24 | 1.11 | 1.02 | 0.92 | 1.99 | 2.08 | 2.13 | 2.27 | 2.22 | 2.55 | 2.57 |
ANI Pharmaceuticals Inc's inventory turnover has shown a fluctuating trend over the past few years, starting at 1.33 in March 2020 and reaching 2.04 by December 2024. This indicates that the company is managing its inventory more efficiently and turning it over at a faster rate.
The receivables turnover and payables turnover ratios are not available, suggesting that ANI Pharmaceuticals does not disclose this information or does not have significant receivables and payables turnover activities.
The working capital turnover ratio has shown some variation, dropping from 2.57 in March 2020 to 0.92 in December 2021, before gradually recovering to 1.84 by December 2024. This indicates that the company's efficiency in utilizing its working capital has improved over time, albeit with some fluctuations.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 178.56 | 201.68 | 181.02 | 186.46 | 206.33 | 236.62 | 255.19 | 266.02 | 277.08 | 256.69 | 264.15 | 264.17 | 296.37 | 246.73 | 283.89 | 256.31 | 254.63 | 268.69 | 254.80 | 274.93 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
ANI Pharmaceuticals Inc's Days of Inventory on Hand (DOH) has shown some fluctuations over the period under review. The company started with around 275 days of inventory on hand in March 2020, which decreased to around 186 days by March 2024. However, there were fluctuations in between, reaching a peak of around 296 days by December 2021. Overall, ANI Pharmaceuticals Inc seems to have managed its inventory more efficiently towards the end of the period.
Regarding Days of Sales Outstanding (DSO) and Number of Days of Payables, the data provided indicates that these ratios were not available or provided as blank for all the periods mentioned. Without this information, it is challenging to assess the company's efficiency in collecting receivables and managing payables.
In conclusion, while ANI Pharmaceuticals Inc's Days of Inventory on Hand metric showed some volatility, the lack of information on Days of Sales Outstanding and Number of Days of Payables limits a more comprehensive analysis of the company's overall activity ratios and efficiency in managing working capital.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | — | — | — | — | — | — | 9.05 | 8.29 | 7.32 | 6.61 | 5.74 | 4.29 | 4.10 | 5.38 | 5.29 | 5.23 | 5.05 | 4.93 | 4.95 | 5.04 |
| Total asset turnover | 0.48 | 0.43 | 0.59 | 0.57 | 0.54 | 0.50 | 0.47 | 0.47 | 0.42 | 0.38 | 0.33 | 0.30 | 0.28 | 0.45 | 0.44 | 0.46 | 0.45 | 0.43 | 0.42 | 0.42 |
The fixed asset turnover ratio for ANI Pharmaceuticals Inc has shown an increasing trend over the past few years, indicating that the company is generating more revenue per dollar invested in fixed assets. The ratio increased from 5.04 in March 2020 to 7.32 in December 2022, peaking at 9.05 in June 2023. This suggests that the company has been efficiently utilizing its fixed assets to generate sales.
On the other hand, the total asset turnover ratio has been more volatile, fluctuating between 0.28 and 0.59 during the same period. This ratio measures the company's ability to generate sales from its total assets. While the ratio showed an increasing trend from March 2020 to December 2023, reaching a peak of 0.59 in June 2024, it experienced a significant decline in December 2021 before rebounding.
Overall, the increasing trend in the fixed asset turnover ratio signifies improved efficiency in utilizing fixed assets, while the total asset turnover ratio fluctuates more, indicating variations in the company's overall asset utilization efficiency. Investors and stakeholders may interpret these ratios in conjunction with other financial metrics to assess the company's operational performance and efficiency.